Pharma News, 2019

Drones can reach critically-ill patients three minutes faster than paramedics in busy cities, according to research.

Amgen's Repatha is facing competition from Regeneron and Sanofi's Praluent, and there could be a new rival in the cholesterol market soon.

GSK has nabbed an expanded FDA nod for Zejula use in recurrent ovarian cancer beyond those with BRCA mutations as long as the tumor have a homologous recombination deficiency.

Construction began in May on WuXi Biologics' €325 million biologics plant in Dundalk, Ireland which is forecast to employ up to 400 when it is finished in 2021.

Cancer drug innovation and Emerging Market sales underlie an upward rerating at AstraZeneca.

A test that can tell whether bacteria is resistant to antibiotics in just 45 minutes has been created by scientists.

On October 23, 2019,the Food and Drug Administration approved niraparib (ZEJULA, Tesaro, Inc.

(Reuters) - Eli Lilly and Co will target cancer drug developers for deals, Chief Executive Officer Dave Ricks said on a post-earnings conference call on Wednesday.

NEW YORK/BOSTON (Reuters) - Teva Pharmaceutical Industries Ltd’s proposed $23 billion drug giveaway to settle thousands of U.

LOS ANGELES (Reuters) - United Parcel Service Inc’s (UPS.

You can see the long, thin fibers of skeleton muscle in this close-up of prosciutto ham.

Trikafta (elexacaftor/ivacaftor/tezacaftor) is the first triple combination therapy available to treat patients with the most common cystic fibrosis mutation.